DDAH1 and prostate cancer: In 2011, a proteomics and pathway analysis study by Ummanni et al. identified DDAH1 overexpression in histologically characterized prostate cancer tissue, and highlighted its potential as a novel biomarker for prostate cancer development and/or progression (185).